BioCardia - Warrants (26/07/2022) Accounts Payable

The latest accounts payable for BCDAW is $820K as of March 2026. That compares with $820K in the prior-year period — up 0.2% year over year. Investors often review this figure alongside BioCardia - Warrants (26/07/2022)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, BCDAW's accounts payable moved from $820K to $820K — a 0.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioCardia - Warrants (26/07/2022)'s operating scale or balance-sheet position.

A accounts payable figure of $820K for BCDAW is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting BCDAW's accounts payable ($820K), review year-over-year change from $820K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BioCardia - Warrants (26/07/2022)'s accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.